1. At a Glance – The CDMO Kingpin Nobody Talks About Loudly Enough
Akums Drugs & Pharmaceuticals is trading at ₹488 with a market cap of ₹7,694 crore. In the last three months, the stock has delivered a solid 16.2% return — not exactly multibagger fireworks, but definitely not sleeping either.
Stock P/E stands at 23.8 versus industry P/E of 27.9. ROE is 17.2%, ROCE 16.2%, debt-to-equity just 0.03 (basically allergic to debt), and interest coverage at 5.63. Quarterly revenue came in at ₹1,160 crore with PAT of ₹78.5 crore (screener TTM shows ₹324 crore PAT). OPM stands at 10.9%.
But here’s the spicy part: Q3 FY26 revenue grew 14.8% YoY and PAT jumped 29.5% YoY (as per earnings presentation). EBITDA margin improved to 12.7%.
So the real question is — how is a company with 30.2% CDMO market share in India trading below sector multiples?
Let’s dissect.
2. Introduction – Pharma’s Invisible Factory
Most people know Cipla, Sun Pharma, Dr. Reddy’s. But who actually manufactures a large chunk of what these companies sell?
Enter Akums.
Established in 2004, Akums is India’s largest India-focused CDMO (Contract Development & Manufacturing Organization). In FY24, it had 30.2% market share in the Indian CDMO market — up from 26.7% in FY21.
Translation? One out of every three outsourced pharma products likely passed through Akums.
They manufacture 4,146 commercialized formulations across 60+ dosage forms. Tablets, injectables, lyophilized vials, gummies (yes, pharma gummies), mouth-melting powders — the works.
They manufactured for 26 of the top 30 Indian pharma companies in FY24.
And 94.8% revenue comes from existing clients. That’s sticky business.
Now ask yourself — would big pharma risk regulatory compliance by shifting CDMO vendors casually?
Exactly.
3. Business Model – WTF Do They Even Do?
Akums operates across three major segments:
- CDMO (78.2% revenue)
- Branded & Generics (16.8%)
- APIs (5%)
CDMO is the crown jewel.
They manufacture for other pharma companies who don’t want to set up manufacturing plants. Because let’s be honest — building pharma plants is expensive, heavily regulated, and headache-inducing.
Akums has
